India Diabetes Market information, by Type (Type 1, Type 2, and Gestational diabetes), by Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others), by Devices (Blood glucose monitoring devices, Diabetes management devices, and others) by Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery and others) - Forecast to 2027

Market Synopsis of India Diabetes Market:

Market Scenario:

Diabetes is a chronic metabolic disease that cause high blood sugar due to which body becomes incapable of producing insulin. According to World Health Organization (WHO), India had 69.2 million people living with diabetes (8.7%) in 2015. About 90% of the patients are suffering from Type 2 diabetes. Increasing awareness, increasing number of patients, untouched rural market, increasing urbanization, developing healthcare infrastructure and increasing spending on healthcare are driving the market for diabetes in India. India Diabetes Market size is expected to grow at an average CAGR of 6.5% during 2016-2023. The Market is growing rapidly. India Diabetes Market is expected to grow US$ 7441.6 million by 2023 from US$ 4778.7 million in 2016.

Study objectives of India Diabetes Market:

• To provide detailed analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Indian Diabetes Market


• To provide insights about factors affecting the market growth


• To analyze the India Diabetes Market based on various factors - price analysis, supply chain analysis, Porters Five Forces analysis etc.


• To provide historical and forecast revenue of the market segments and sub-segments


• To provide detailed analysis of the market with respect to the current market size and future prospective


• To provide detailed analysis of the market for segments by type, by test, by devices, by treatment, and its sub-segments.


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Market

India Diabetes Market Share by Devices, 2016 (%):

 Segments:      

India Diabetes Market has been segmented on the basis of type which comprise Type 1, Type 2, and Gestational diabetes. On the basis of test market is segmented into Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others. On the basis of devices, it is segmented into Blood glucose monitoring devices, Diabetes management devices, and others. On the basis of treatment, the market is segmented into Medications, Insulin therapy, Transplantation, Bariatric surgery and others.

Regional Analysis:

Considering the scenario of the Indian diabetes market, western region is believed to be the largest market for diabetes. Moreover the Eastern and Northern regions are also growing and second-largest market for India Diabetes. On the other hand, Southern Indian market is expected to grow at a significant rate in India diabetes during the forecasted period. Central region is likely to have a limited but moderate growth in the market.

Key Players:                                                         

• Novo Nordisk A/S (Denmark)


• USV Private Limited (India)


• sanofi-aventis U.S


• LLC (US)


• Novartis AG (Switzerland)


• Merck & Co., Inc. (US)


• Becton Dickinson and Company (US)


• Roche Diabetes Care, Inc.(US),


• Johnson & Johnson Services, Inc.(us)


• Bayer AG (Germany)


• Ypsomed (Switzerland)

The report for India Diabetes Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Intended Audience

• Hospitals and Clinics


• Diabetes drugs and devices manufacturers


• Diabetes drugs and devices suppliers


• Government and Independent Regulatory Authorities


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Medical Research Laboratories


• Potential Investors

Report Scope:

Report Attribute/Metric	Details
Market Size	USD 7441.6 Million
CAGR	2016-2023: 6.5%
Base Year	2019
Forecast Period	2027
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Type, Test, Devices, Treatment
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Novo Nordisk A/S (Denmark), USV Private Limited (India), sanofi-aventis U.S. LLC (US), Novartis AG (Switzerland), Merck & Co., Inc. (US), Becton Dickinson and Company (US), Roche Diabetes Care, Inc.(US),Johnson & Johnson Services, Inc.(us), Bayer AG (Germany), Ypsomed (Switzerland)
Key Market Opportunities	Research and developments
Key Market Drivers	Increasing number of patients Increasing urbanization Healthcare infrastructure Increasing spending on healthcare

Speak to Analyst Ask for Customization